- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06169527
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab (DUPILAB)
December 12, 2023 updated by: Sanofi
French Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France.
Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information.
The decision of initiation of the treatment is independent to the study's participation.
The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France.
At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.
Study Overview
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Trial Transparency email recommended (Toll free for US & Canada)
- Phone Number: option 6 800-633-1610
- Email: Contact-US@sanofi.com
Study Locations
-
-
-
Argenteuil, France, 95100
- Recruiting
- Investigational Site Number: 2500021
-
Clermont Ferrand, France, 63003
- Recruiting
- Investigational Site Number: 2500006
-
Pau, France, 64000
- Recruiting
- Investigational Site Number: 2500016
-
Saint Nazaire, France, 44600
- Recruiting
- Investigational Site Number: 2500026
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
The population of interest for this study will be patients in France aged 6 years old or more with a diagnosis of AD either severe or moderate to severe (depending on age group) who initiate dupilumab in real world setting.
The study will be conducted in real conditions of practice, dupilumab will be prescribed at the sole initiative of the participating physician irrespective of patient enrolment decision.
Description
Inclusion Criteria:
- Male or female, 6 years or older.
- Initiating treatment with dupilumab for AD according to French-specific prescribing information (≥ 12 years old: moderate to severe AD versus 6-11 years old: severe AD). The decision of initiation of the treatment is independent to the study's participation.
- Able to understand and complete study-related questionnaires.
- Signed informed consent form. For participants <18 years old, Informed consent form signed by the parent/legal guardian and participant's assent obtained.
Exclusion Criteria:
- Patients who have a contraindication to the drug according to the French-specific prescribing information label.
- Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments.
- Patients currently participating in any interventional clinical trial.
- Patients previously treated with dupilumab.
- Patients under tutorship or curatorship; patients under safeguard of justice or deprived of his/her liberty by an administrative or court decision.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with AD treated with dupilumab
Patients ≥6 years of age in whom dupilumab therapy was initiated to treat their AD according to French-specific prescribing information.
|
Dupilumab cohort
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic characteristics of participants who receive dupilumab for AD
Time Frame: At baseline
|
Including age, gender, educational level, socio-professional category
|
At baseline
|
Weight characteristics of participants who receive dupilumab for AD
Time Frame: At baseline
|
At baseline
|
|
Height characteristics of participants who receive dupilumab for AD
Time Frame: At baseline
|
At baseline
|
|
Medical history characteristics of participants who receive dupilumab for AD
Time Frame: At baseline
|
including previous treatments for AD, relevant medical history, family history of atopy
|
At baseline
|
Comorbidities and treatments change from baseline
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Atopic comorbidities and treatments change from baseline
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in lifestyle habits of participants who receive dupilumab for AD
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
|
Including alcohol, tobacco, CBD and cannabis consumption
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
|
Change from baseline in dupilumab dose
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in dupilumab administration
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in dupilumab compliance with treatment
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in dupilumab temporary or permanent discontinuation
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in dupilumab treatment switch to another therapy
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change from baseline in dupilumab treatment for concomitant AD treatments
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
|
Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)
Time Frame: At month 6, month 12, month 18, month 24, month 30, month 36
|
PGATE for patients ≥ 12 years of age: an internally developed and validated instrument allowing patients to rate their opinion and perceived treatment effect.
Ratings are on a 5-point Likert scale from 1 being "Poor" and 5 being "Excellent".
|
At month 6, month 12, month 18, month 24, month 30, month 36
|
Change in eczema severity using the Eczema Area and Severity Index (EASI)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
EASI is a validated measure used to assess severity and extent of AD at each body region by multiplying the lesions characteristics score x the body area score x multiplier.
Four AD disease characteristics -erythema, thickness (induration, population, and oedema), scratching (excoriation), and lichenification - will each be assessed for severity by the observing physician, as follows: 0 = none, absent; 1=mild (just perceptible); 2=Moderate (obvious); 3=Severe.
The area score ranges from 0 to 6 is determined as follows: 0= 0% (no active eczema in region); 1= 1-9%; 2= 10-29%; 3= 30-49%; 4= 50-69%; 5= 70-89%; 6= 90-100% (entire region affected by eczema).
The multiplier is determined according to the region affected and the age of the patient: 0.1 or 0.2 for patients < 8 years old (head/neck), 0.2 (upper limbs), 0.3 (trunk), 0.4 or 0.3 for patients < 8 years old (lower limbs).
A higher score means higher AD severity.
Scores range from 0 (no disease) to 72 (maximal disease severity).
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
ADCT for patients aged ≥ 12 years of age: a validated, brief and easily scored tool consisting of six concise questions allowing to rate the different dimensions of patient-perceived AD control, to foster communication between patients and their physicians and help appropriate decision-making.
The instrument includes 6 items, with a 7-day recall period: overall severity of symptoms, frequency of intense episodes of itching, severity of bother, frequency of sleep impact, severity of daily activities impact and severity of mood or emotions impact.
Each item is rated on a 5-point Likert scale, ranging from 0 (none/ not at all/ no nights) to 4 (very severe/ everyday/ extremely/ every night); the total score ranges from 0 to 24, which is the summation of the responses to all the items.
A total score of ≥7 points was derived as the threshold to identify patients "not in control", based on optimal sensitivity/ specificity values.
The higher the score, the less AD is controlled.
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in Worst-Itch Numeric Rating Scale (WI-NRS)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
WI-NRS will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in sleep disturbance NRS
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days (adult, pediatric and adolescent patients), completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
PGADS for patients ≥ 12 years of age: an internally developed and validated instrument allowing to the patients to rate their AD-related overall well-being.
Patients will be asked: "Considering all the ways in which your eczema affects you, how well are you doing?" Response choices will be from 1 being "Poor" to 5 being "Excellent".
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
CGAD for patients 6 to 11 years of age: an internally developed and validated instrument allowing to the caregivers to rate their child's AD-related overall well-being.
Caregivers will be asked: "Considering all the way in which the eczema affects your child, how well is your child doing?".
Response choices will be 1 being "Poor" to 5 being "Excellent".
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in Dermatology Life Quality Index (DLQI)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
DLQI for patients ≥ 16 years (or cDLQI for patients < 16 at baseline) are 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life in adults and pediatrics, respectively.
The format is a simple response (0 to 3 where 0 is "not at all" and 3 is "very much") to 10 items, which assess quality of life over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor quality of life.
Patients 6-11 years old will be assisted for questionnaire completion.
A cDLQI's cartoon version could be also used for patients from 6 to 11 years old.
If a patient turns 16 years old during the study, they will switch to DLQI.
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)
Time Frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
The EQ-5D-3L consists of 2 parts:
|
At baseline, month 6, month 12, month 18, month 24, month 30, month 36
|
Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)
Time Frame: At month 6, month 12, month 18, month 24, month 30, month 36
|
WPAI-AD for adults and WPAI-CIQ-AD for adolescents is a questionnaire designed to assess the impact of AD on the patient's productivity.
The WPAI-AD is the version of the original generic WPAI that is specific to AD.
It is a 6-item, validated questionnaire to measure impairments in work and activities over a 7-day recall period.
The WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
If a patient turns 18 years old during the study, this one will switch to WPAI-AD.
|
At month 6, month 12, month 18, month 24, month 30, month 36
|
Number of Adverse Events (AE)
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
AEs for dupilumab and/or concomitant treatments will be collected throughout the study.
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
Change from baseline in Drug Survival
Time Frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes.
If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization.
The drug survival will be illustrated using a Kaplan-Meier plot.
|
At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 28, 2023
Primary Completion (Estimated)
November 29, 2027
Study Completion (Estimated)
November 29, 2027
Study Registration Dates
First Submitted
December 5, 2023
First Submitted That Met QC Criteria
December 5, 2023
First Posted (Actual)
December 13, 2023
Study Record Updates
Last Update Posted (Estimated)
December 14, 2023
Last Update Submitted That Met QC Criteria
December 12, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBS17668 (Other Identifier: Sanofi Identifier)
- U1111-1279-3469 (Registry Identifier: ICTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants.
Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of ScalpUnited States
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
University of RochesterNot yet recruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Erasmus Medical Center; Prothya BiosolutionsRecruitingAtopic Dermatitis | Atopic Dermatitis EczemaNetherlands